Search alternatives:
significant challenges » significant challenge (Expand Search), significant changes (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
challenges decrease » challenges case (Expand Search)
significant challenges » significant challenge (Expand Search), significant changes (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
challenges decrease » challenges case (Expand Search)
-
2381
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2382
-
2383
-
2384
-
2385
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2386
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2387
-
2388
-
2389
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2390
-
2391
-
2392
-
2393
-
2394
-
2395
-
2396
-
2397
-
2398
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
2399
-
2400